TG Therapeutics

TGTX NASDAQ
6.93
-0.32
-4.41%
Closed 17:55 06/24 EDT
Open
7.25
Prev Close
7.25
High
7.46
Low
6.92
Volume
1.20M
Avg Vol (3M)
1.69M
52 Week High
14.10
52 Week Low
3.320
% Turnover
1.32%
Market Cap
629.49M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers TG Therapeutics TGTX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
MORE >

Recently

Name
Price
%Change